New research questioned old assumptions

https://www.medpagetoday.com/neurology/painmanagement/119247

In January 2025, we reported that some adverse events associated with gabapentin (Neurontin) may have been overestimated. Since then, new risks related to gabapentin emerged and prescribing continued to rise. Here’s what we learned about gabapentin in 2025.

Often championed as a safer alternative to opioids and prescribed off-label for chronic pain, gabapentin is approved officially for postherpetic neuralgia and partial-onset seizures. The drug’s label carries serious warnings about dizziness, suicidal thoughts, respiratory depression, and other adverse effects. Another gabapentinoid, pregabalin (Lyrica), is approved for the same indications, plus neuropathic pain and fibromyalgia.

New Risks, Rising Prescriptions

Perhaps the most startling finding about gabapentin in 2025 came from a study that suggested gabapentin prescriptions for chronic low back pain were linked with increased risks of dementia and mild cognitive impairment, especially in younger people.

Among more than 52,000 adults tracked for 10 years in U.S. healthcare claims records, chronic pain patients with six or more gabapentin prescriptions had a higher incidence of dementia and mild cognitive impairment compared with those not prescribed gabapentin. Dementia risk was more than double — and mild cognitive impairment risk was more than triple — among those ages 35 to 49, the researchers reported in Regional Anesthesia & Pain Medicine. A similar pattern emerged among those ages 50 to 64 years.

A dose-response pattern emerged: pain patients who filled 12 or more prescriptions faced greater risks than those with fewer refills. This raised critical questions, especially as gabapentin’s off-label use continued to climb, the study authors noted.

A new report also documented gabapentin’s meteoric rise since 2010. Gabapentin was the fifth most dispensed drug in U.S. retail pharmacies in 2024, CDC researchers said in Annals of Internal Medicine.

Prescriptions per 1,000 people more than doubled from 2010 to 2024, while the number of Americans taking gabapentin soared from 5.8 million to 15.5 million. Statewide policy changes after 2016 — including drug monitoring programs and reclassification of gabapentin as a controlled substance — may have slowed the pace of growth in some places, the CDC team suggested.

In 2025, a claims analysis showed that stroke patients who started gabapentin for pain within 30 days of hospital discharge often received a yearlong gabapentin prescription. The study, posted on medRxiv and not yet peer-reviewed, was the first to provide insights into real-world gabapentin treatment patterns among older Medicare stroke survivors, the researchers said.

More recently, an analysis in JAMA Network Open questioned whether prescribing cascades — a pattern in which the adverse effects of one medication are treated with another — were tied to gabapentinoid-induced edema. A study of medical records of gabapentin-treated military veterans showed that clinicians almost never explicitly considered gabapentinoid effects when treating edema with loop diuretics, commonly attributing fluid build-up to congestive heart failure or venous stasis. Nearly one in four patients had potential harms from a resulting prescribing cascade.

Global research echoed U.S. prescribing concerns. Uncertainty was a recurring theme in a 2025 review of qualitative studies in the European Journal of Pain, with clinicians worldwide saying there was lack of guidance for starting, monitoring, or tapering gabapentinoid use.

Old Warnings Reconsidered

Contrary to previous findings, a commercial claims analysis in 2025 suggested that gabapentin was not associated with greater risk of falls in older adults with neuropathy or fibromyalgia when compared with duloxetine (Cymbalta).

The largest studies that previously estimated gabapentin’s fall risks compared its use against patients who didn’t use medications, the researchers noted in Annals of Internal Medicine. This might mean gabapentin’s risks were overestimated, which could lead to pain being undertreated, they observed. Including an active comparator like duloxetine helped lower the chance that outcomes were driven by confounding by indication.

Long-standing fears about gabapentinoids and self-harm also were re-examined in a U.K. self-controlled case series. That study, published in The BMJ, showed that self-harm risk rose in the 90 days before gabapentinoid treatment, persisted during the early treatment period before dropping to a reference level, then rose again within 14 days after treatment stopped.

“These findings do not support a direct effect of gabapentinoid treatment on self-harm but underscore the necessity for close patient monitoring of self-harm throughout the gabapentinoid treatment journey,” the study authors stated.

Additional research in 2025 illustrated that pregabalin carried a higher risk of heart failure compared with gabapentin among Medicare beneficiaries with chronic noncancer pain. The finding prompted calls from researchers and editorialists in JAMA Network Open for thorough cardiovascular risk assessments before prescribing pregabalin to older patients.

Filed under: General Problems | 3 Comments »

https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-raise-us-prices-350-medicines-despite-pressure-trump-2025-12-31/

• Number of hikes rises from same time a year ago
• Median list price increase is 4%, in line with 2025
• Includes 5 drugmakers who struck pricing deals with Trump administration

NEW YORK, Dec 31 (Reuters) – Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors.

The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs. The median of this year’s price hikes is around 4% – in line with 2025.

The increases do not reflect any rebates to pharmacy benefit managers and other discounts.

DRUGMAKERS ALSO CUT SOME PRICES

Drugmakers also plan to cut the list prices on around nine drugs. That includes a more than 40% cut for Boehringer Ingelheim’s diabetes drug Jardiance and three related treatments.

Boehringer Ingelheim and Eli Lilly (LLY.N)

, opens new tab, which sell Jardiance together, did not immediately respond to requests for comment on the reason for the price cuts.

Jardiance is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026. Under those negotiations, Boehringer and Lilly slashed the Jardiance price by two-thirds.

U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay in similarly wealthy nations.

The increases on 350 medicines come even as Trump has struck deals with 14 drugmakers on prices of some of their medicines for the government’s Medicaid program for low-income Americans and for cash payers. Pfizer (PFE.N)

, opens new tab, Sanofi (SASY.PA), opens new tab, Boehringer Ingelheim, Novartis (NOVN.S), opens new tab and GSK (GSK.L)

, opens new tab are among those companies and also plan to raise prices on some drugs on January 1.

“These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston.

Rome said the companies seem to be maximizing prices while negotiating discounts behind the scenes with health and drug insurers and then setting yet another price for direct-to-consumer cash-pay sales.

U.S. flag and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights

, opens new tab

An HHS spokesman declined to comment.

KEEPING UP WITH INFLATION

Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, migraine pill Nurtec, and COVID treatment Paxlovid, as well as some administered in hospitals such as morphine and hydromorphone.

Most of Pfizer’s increases are below 10%, except for a 15% hike of COVID vaccine Comirnaty, while some of its relatively inexpensive hospital drugs saw more than four-fold increases.

Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.

“The modest increase is necessary to support investments that allow us to continue to discover and deliver new medicines as well as address increased costs throughout our business,” the company said.

Larger U.S. drug price increases were once far more common. Drugmakers have scaled them back due to criticism from lawmakers and new government policies, such as penalizing companies that charge Medicare program prices that rise faster than inflation.

European drugmaker GSK plans to increase prices on around 20 drugs and vaccines from 2% to 8.9%. The drugmaker said it is committed to reasonable prices and the hikes are needed to support scientific innovation.

Sanofi and Novartis did not respond to requests for comment.

More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.

3 Axis is a consulting firm that works with pharmacist groups, health plans and some pharmaceutical industry-related groups on drug pricing and supply chain issues. It is a related entity to, and shares staff with, drug pricing non-profit 46brooklyn.

Filed under: General Problems | Leave a Comment »

Filed under: General Problems | Leave a Comment »

I ask perplexity.AI:

under trump RX how and where are these Rxs going to be filled, local community pharmacies, mail order or some other way?

TrumpRx is structured so that many of the prescriptions it targets never touch a local pharmacy at all; they are routed to manufacturers’ contracted mail/specialty pharmacies via TrumpRx.gov and the drugmakers’ own DTC portals, with community pharmacies competing only on price for patients who choose not to use the portal.

How TrumpRx fills prescriptions

• Primary channel is DTC mail/specialty: TrumpRx.gov does not itself sell or dispense medications; it directs patients to the manufacturer’s direct‑to‑consumer site, which then uses a contracted fulfillment or specialty pharmacy to ship the drug.

• Valid Rx still required: Patients still need a prescription from a prescriber, but the Rx is sent to the manufacturer’s partner pharmacy rather than the patient’s usual community pharmacy if they choose the TrumpRx route.

• Cash‑pay only at point of sale: The discounted TrumpRx prices are described as cash prices that cannot be combined with insurance at the point of sale, which reinforces channeling fills through the DTC/mail model rather than standard plan‑PBM retail networks.

Role of local community pharmacies

• Indirect participation only: Community pharmacies are not integrated “TrumpRx network” providers; instead, they remain the default channel for patients who stick with their insurance or ask the local pharmacy to match TrumpRx cash prices.

• Competitive pressure, not volume growth: Analyses aimed at pharmacies warn that TrumpRx introduces “channel displacement,” as manufacturers’ DTC programs and mail fulfillment siphon away some prescriptions that would otherwise be filled at community pharmacies.

• Patient choice on each Rx: For a given drug, the patient (and prescriber) can either:

  • Fill through the usual route (local pharmacy, billed to PBM/plan), or

  • Use TrumpRx.gov and shift that prescription to the manufacturer’s mail/specialty partner under a discounted cash arrangement

Where most TrumpRx volume is likely to go

• High‑cost specialty and brand products: The initial deals (Pfizer, Novartis, Sanofi, Eli Lilly, Novo Nordisk, etc.) emphasize big‑ticket brands—GLP‑1s, MS drugs, Hep C therapies, cholesterol biologics—where manufacturers can afford steep “TrumpRx” discounts in exchange for MFN/tariff relief.

• Fulfilled by limited networks: Those products are already heavily specialty/mail‑pharmacy dominated, so TrumpRx volume is expected to concentrate in limited networks or manufacturer‑owned/contracted specialty pharmacies rather than in broad retail community networks.

• Medicaid/Medicare carve‑outs separate: Some Trump administration agreements focus on Medicaid and Medicare MFN‑style pricing within existing plan structures (i.e., still running through PBMs and standard networks); that business would continue to flow through local pharmacies when plans keep retail networks intact, but that’s parallel to, not part of, the TrumpRx DTC cash channel.

Net effect on dispensing channels

• TrumpRx channel: Predominantly mail/specialty fulfillment linked to manufacturer DTC sites; community pharmacies touch those prescriptions only if a given manufacturer allows local pharmacy fulfillment and the patient opts in.

• Traditional insurance channel: Local community and chain pharmacies continue to fill insured prescriptions, but may lose some higher‑margin branded volume when patients or plans migrate to TrumpRx‑linked discounts.

• PBM role weakened but not removed: For the TrumpRx cash‑pay segment, PBMs are largely bypassed, while they remain central for insured fills through existing networks that still include community pharmacies.

so any money paid under Trump Rx will not go toward the pt’s annual Rx deductible and couldn’t Trump Rx accelerate the closing of community pharmacies – especially hitting low income and rural area the hardest. Mail order is hard pressed to provide “need it now ” – acute meds and are notorious for not always maintain proper temperature during shipment – often compromising the potency of Rx medications because of meds getting too hot or too cold during shipment. Doesn’t Trump Rx run the risk of causing few community pharmacies being available, resulting in farther distances for pts to travel and/or poorer services?

Yes. TrumpRx transactions are typically treated as standalone cash purchases, so in most cases they will not accrue toward a patient’s annual deductible or out‑of‑pocket maximum, and the model carries very real risks for community pharmacy viability, especially in low‑income and rural areas.

Deductibles and out‑of‑pocket tracking

• Cash ≠ deductible credit in most plans: Analyses aimed at consumers make clear that TrumpRx is a cash‑price option that sits outside the insurance claim stream, meaning amounts paid usually will not be captured by deductible/OOP tracking unless a plan builds in a specific “file a claim” workaround.

• Plan incentives may conflict: Employer and Medicare commentary frames TrumpRx as “another way” to manage costs, not a replacement for Part D or commercial coverage, and flags that using it can delay reaching the deductible, which can backfire once a patient moves into a higher‑spend phase of care.

Impact on community pharmacies

• Channel displacement, not just margin squeeze: Legal and consulting analyses describe the primary TrumpRx risk to pharmacies as “channel displacement” when manufacturers sell direct through the portal and bypass pharmacies entirely or restrict discounts to DTC/mail‑order fills.

• Greatest vulnerability: independent, rural, low‑income areas: Commentaries from rural owners and trade groups warn that when high‑revenue brand prescriptions move to DTC/mail channels, independents lose both revenue and patient foot traffic that supports broader services, with rural communities hit hardest because those pharmacies often function as the only local health access point.

Likely downstream effects

• Acceleration of closures in already thin‑margin markets, increasing “pharmacy deserts” and forcing longer patient travel distances.

• Erosion of face‑to‑face counseling, immunization, and chronic‑care services bundled around the dispensing function, which are disproportionately important in rural settings.

Mail‑order limitations and temperature risks

• Poor fit for “need it now” meds: TrumpRx’s DTC model is geared to chronic and high‑cost brands, not true acute/urgent fills; even proponents acknowledge that acute antibiotics, short‑course steroids, and post‑op meds are not well suited to multi‑day shipping.

• Documented temperature‑control problems: Multiple investigations and professional society reports have found that mail‑order medications are frequently exposed to temperatures outside the 68–77 °F “room temperature” range, with cargo spaces hitting extremes that can compromise drug stability.

• Regulation lagging practice: Pharmacy boards and researchers have called for tighter regulation and temperature monitoring across mail‑order shipments, noting that current industry practices reserve robust controls for a minority of clearly temperature‑sensitive products, not for the bulk of room‑temperature items that may still be vulnerable to heat/cold excursions.

Net risk to access and quality

• Fewer brick‑and‑mortar options: By shifting profitable brand volume into DTC/mail and cash channels that bypass PBM‑retail networks, TrumpRx increases economic pressure on community pharmacies already battered by DIR clawbacks, low reimbursements, and shrinking front‑end sales, increasing the likelihood of further closures.

• Worse service for vulnerable patients: As rural and low‑income neighborhoods lose pharmacies, patients face longer travel distances, reduced access to acute “need it now” medications, more dependence on mail order with imperfect temperature controls, and less access to pharmacist‑provided clinical services.

Put bluntly, TrumpRx can help certain patients with specific expensive drugs in the short term, but structurally it tends to undermine local pharmacy infrastructure and does little to solve the time‑sensitive and quality‑of‑handling issues that community pharmacies are uniquely positioned to address.

Filed under: General Problems | Leave a Comment »

1. https://www.fdli.org/2018/08/update-the-dea-quota-system/
2. https://usafacts.org/articles/are-fentanyl-overdose-deaths-rising-in-the-us/
3. https://www.kff.org/mental-health/opioid-deaths-fell-in-mid-2023-but-progress-is-uneven-and-future-trends-are-uncertain/
4. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
5. https://www.ecfr.gov/current/title-21/chapter-II/part-1303
6. https://uscode.house.gov/view.xhtml?req=%28title%3A21+section%3A826+edition%3Aprelim%29+OR+%28granuleid%3AUSC-prelim-title21-section826%29&f=treesort&edition=prelim&num=0&jumpTo=true
7. https://www.dea.gov/operational-division/diversion
8. https://museum.dea.gov/sites/default/files/2021-09/Diversion%20Control%2007102019–Accessible.pdf
9. https://www.oregon.gov/oha/ph/preventionwellness/substanceuse/opioids/pages/fentanylfacts.aspx
10. https://www.federalregister.gov/documents/2019/10/23/2019-21989/management-of-quotas-for-controlled-substances-and-list-i-chemicals
11. https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-057)(EO-DEA217)_Researchers_Manual_Final_signed.pdf
12. https://www.congress.gov/crs-product/R45948
13. https://www.dea.gov/press-releases/2020/04/07/dea-takes-additional-steps-allow-increased-production-controlled
14. https://www.ashp.org/Advocacy-and-Issues/Key-Issues/Drug-Shortages/ASHP-and-Healthcare-Groups-Urge-the-DEA-to-Adjust-APQs-to-Mitigate-Ongoing-Drug-Shortages
15. https://www.pharmacytimes.com/view/debunking-the-myths-of-controlled-substance-quotas
16. https://www.federalregister.gov/documents/2024/12/17/2024-30023/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment
17. https://www.deadiversion.usdoj.gov/quotas/quotas.html
18. https://www.federalregister.gov/documents/2025/11/28/2025-21509/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of
19. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2833721
20. https://www.osc.ny.gov/reports/continuing-crisis-drug-overdose-deaths-new-york

Filed under: General Problems | 2 Comments »

CMS is cracking down on it in Medicare Advantage while expanding its use in traditional Medicare

https://www.medpagetoday.com/practicemanagement/reimbursement/119157

Earlier this year, the Centers for Medicare & Medicaid Services (CMS) announced an agreement with Medicare Advantage plans to lessen the use of prior authorization, but the agency also said it would conduct a demonstration project looking at expanding its use in traditional Medicare. In this story, we look at what has happened so far and what experts are watching for in the future.

As the year comes to a close, the Trump administration seems to be going in two different directions when it comes to the use of prior authorization in Medicare.

On the one hand, there is the effort by CMS to crack down on the use of prior authorization among Medicare Advantage plans and other federal and private insurance programs. In June, HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz, MD, held a roundtable with industry stakeholders.

The participants included America’s Health Insurance Plans, the Blue Cross Blue Shield Association, CareFirst BlueCross BlueShield, Centene Corporation, Cigna, Humana, Kaiser Permanente, and UnitedHealthcare. The participating insurers pledged to, among other things:

• Standardize electronic prior authorization submissions
• Reduce the volume of medical services subject to prior authorization by Jan. 1
• Implement real-time approvals for most requests by 2027
• Ensure medical professionals review all clinical denials

Prior Regulation

That agreement came on top of regulatory changes to prior authorization that were already underway. For example, CMS issued a final rule on interoperability and prior authorization in January 2023, and more regulations later that year as part of the Medicare Advantage and Part D final rule, explained Neil Patil, MPP, policy director at the Medicare Policy Initiative at Georgetown University’s Center on Health Insurance Reform. “Those two rules put a lot of new requirements on plans,” including streamlining the use of electronic prior authorization requests rather than requiring providers to submit requests via phone or fax, Patil said in a phone interview.

In addition, “by law, Medicare Advantage plans have to cover traditional Medicare services,” he said. “A lot of plans were using prior authorization as kind of a way to deny some of the care that beneficiaries are legally entitled to … so CMS put out some new rules saying, ‘You have to follow traditional Medicare laws, regulations, National Coverage Determinations, and Local Coverage Determinations. You can’t just unilaterally deny something that would have been covered under traditional Medicare.'”

But even as CMS is scrutinizing prior authorization in Medicare Advantage, it is also expanding its use — if only a little — in traditional Medicare. In June, CMS announced a new demonstration project in traditional Medicare: the Wasteful and Inappropriate Service Reduction (WISeR) Model. Under the model, “CMS will partner with companies specializing in enhanced technologies to test ways to provide an improved and expedited prior authorization process” under traditional Medicare, the agency said in a press release, adding that the model will help “patients and providers avoid unnecessary or inappropriate care and [will safeguard] federal taxpayer dollars.”

The WISeR Model will test new technologies including artificial intelligence (AI) to see whether they can expedite the prior authorization processes for certain items and services “that have been identified as particularly vulnerable to fraud, waste, and abuse, or inappropriate use,” the press release noted. “These items and services include, but are not limited to, skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis.” Emergency services and inpatient-only services are exempt from the model, which will initially be tested in six states: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington.

Although the model is “voluntary” for providers, “providers and suppliers in the assigned regions will have the choice of submitting prior authorization requests for selected items and services or their claim will be subject to pre-payment medical review,” the agency noted, so either way the claims for the affected services will be reviewed.

Pushback From Congress

The model came in for some immediate pushback on Capitol Hill. “It’s baffling how in one breath the administration is trying to take a victory lap on insurers streamlining prior authorization in Medicare Advantage, and in the other instituting the same delay tactics in traditional Medicare,” Rep. Suzan DelBene (D-Wash.), whose state is one of those included in the model, said in an email to MedPage Today shortly after WISeR was announced. DelBene is the chief sponsor of H.R. 5940, which would prohibit WISeR’s implementation. The bill has 32 co-sponsors, all Democrats. A Senate companion bill introduced by Sen. Patty Murray (D-Wash.) has 17 co-sponsors, also all Democrats.

This is not actually the first time that prior authorization has been used in traditional Medicare, according to Marsha Simon, PhD, adjunct professor of health policy at George Washington University in Washington. Prior authorization has worked well there when it comes to the purchase of electric scooters and the use of ambulances to transport patients to routine dialysis appointments; both of those items had been involved in allegations of fraud or overuse, she said.

“It’s not prior authorization that’s the problem; it’s the vendors who are conflicted,” said Simon. She was referring to the information technology (IT) vendors that CMS has contracted with to implement the WISeR Model. Under the model, the vendors are paid a share of the savings generated by the claims that they deny.

And that’s not their only conflict, according to Patil. With two of the vendors, “we’ve done some digging into them and they have financial and strategic investors tied to Medicare Advantage plans; that’s where we’re concerned about potential indirect conflict-of-interest concerns,” he said. “They could potentially try to make traditional Medicare less popular” by denying lots of claims. In addition, “a few vendors … do have existing relationships with Medicare Advantage plans…. I think this does raise some concerns about the measures CMS has taken to ensure the WISeR Model isn’t inadvertently endorsing Medicare Advantage markets.”

Little Word to Providers

Meanwhile, WISeR is slated to launch on Jan. 1, but doctors in the affected states have heard very little from the vendors about how the program will work. For example, in Washington State, Virtix Health has been assigned as the IT contractor, said Bindu Nayak, MD, vice president of the Washington State Medical Association. But “there really hasn’t been any information from Virtix Health to the healthcare providers,” she said in a phone interview. “I did look at their website and … I noticed they have job listings for physicians to be the ones who will review the claims to be denied … so they are still setting up shop.”

“With traditional Medicare, prior authorizations are not a big part of the picture,” said Nayak, an endocrinologist in Wenatchee, Washington. “I certainly am concerned about Medicare recipients who may find that it is hard to handle [denied] claims; they are a vulnerable group, so to make things harder for them to navigate … is not fair to the patients.”

Asked about the level of communication between vendors and providers, a CMS spokesperson said in an email that “CMS is actively working with WISeR participants and CMS Medicare Administrative Contractors (MACs) on readiness. WISeR participants, MACs, and CMS have been conducting education and outreach to providers in selected states and will continue to do so as the model begins. CMS will continue to work with providers and participants to ensure any issues are rapidly identified and resolved.”

Prior authorization’s benefits should not be overlooked, according to Michael Lutz, managing director at the consulting firm Avalere Health. “I tend to believe there is a role for prior authorization when it’s done correctly, when it’s executed efficiently based on clinical guidelines and well-documented approaches to delivery of care,” he said in a phone interview. “So it does not surprise me when, in a world where we need to be focused on controlling costs and increasing quality, that folks like Medicare are looking to see what prior authorization can bring to the market.”

“If we get rid of prior authorization completely, we lose a lot of the benefits of managed care,” but it needs to be implemented efficiently and in a way that doesn’t interfere with physicians’ workflow, he said. “What I do see across the board is a desire to use technology … to make the process better, to make it less disruptive to patients and members of the health plans, and I do think we can get there.”

One thing Lutz said he’ll be watching is the use of AI in the WISeR Model. “There’s a lot of drive to use AI to help comb through the clinical information and be an aid to the final reviewer as they look at these cases,” he said. “But there’s also a lot of pushback from regulation about how AI can be deployed…. Is regulation going to interrupt the process? Is regulation going to enhance the process of adoption or guide it in certain ways? I think that’s the big question.”

Filed under: General Problems | Leave a Comment »

Some pharmacists are substituting their judgment for that of ordering physicians. The AMA opposes such actions.

https://www.ama-assn.org/practice-management/scope-practice/investigating-pharmacists-refusal-fill-valid-physician-orders

Wayne, New Jersey, ophthalmologist Donald J. Cinotti, MD, is accustomed to the usual delays with having orders filled promptly at area pharmacies. Those can relate to medication shortages, prior authorization and other insurance restrictions, or the occasional instances in which a pharmacist appropriately warns of a potential drug-patient or drug-drug interaction. 

But Dr. Cinotti was taken aback when he heard from an ophthalmology colleague—a DO—in Central New Jersey that a pharmacist had refused to fill that doctor’s prescription because it was “outside the prescriber’s specialty.” Dr. Cinotti’s colleague had ordered a cream to treat a patient’s rosacea, which can increase the risk of the inflamed-eyelid condition blepharitis.

“Outside the prescriber’s specialty” for an ophthalmologist to order a medication for an eyelid condition? That seemed wrong to Dr. Cinotti.

Did the pharmacist perhaps mistake the ophthalmologist’s doctor of osteopathic medicine (DO) degree for the doctor of optometry (OD) degree—with optometrists of course being valued members of the physician-led team, but not permitted to order such medications? Was there a typographical error that led to some DO/OD confusion? No, and no. 

As Dr. Cinotti and his colleagues in New Jersey investigated the matter, they discovered that other ophthalmologists, anesthesiologists and other doctors were encountering instances in which pharmacists appeared to substitute their judgment for the physician’s in refusing to fill orders for sedatives, anxiolytics or dermatologic agents.

“Such refusals contradict American Medical Association policy opposing pharmacists’ authority to initiate, modify or substitute medications outside a physician’s explicit direction, and amount to inappropriate intrusion into the practice of medicine,” Dr. Cinotti noted in a resolution that the American Academy of Ophthalmology introduced at the 2025 AMA Annual Meeting in Chicago. He serves as an alternate delegate for the organization in the House of Delegates.

“Pharmacists are not trained or licensed to make medical diagnoses and their scope of practice does not include the authority to override a physician’s clinical judgment or determine a patient’s treatment plan,” said the resolution, whose recommendations were adopted by delegates with a minor amendment. 

“These denials disrupt patient care, compromise safety, delay medically necessary treatment and may create liability and access issues, particularly for patients with urgent or chronic conditions,” the resolution added. 

More study needed

At the Annual Meeting, physicians’ testimony on the resolution “universally acknowledged that while pharmacists play an important role as part of a physician-led team, they should not have the authority to unilaterally withhold medication from patients after it has been prescribed by a physician,” a reference-committee summary noted. 

To address the issue, delegates at the 2025 Annual Meeting directed the AMA to study the matter and its impact on patients and work with state medical boards and pharmacy boards on it. A report is likely to be issued at the 2026 AMA Annual Meeting in June.

With its action, the House of Delegates reaffirmed “existing policy opposing unauthorized medication substitution, inappropriate pharmacy inquiries and unauthorized treatment modification by pharmacists.”

The AMA also supports legislation or regulatory actions requiring pharmacists and pharmacy chains to either fill a valid prescription or immediately refer the patient to an alternative dispensing pharmacy, with notification to the prescribing physician.

The AMA is fighting scope creep, defending the practice of medicine against scope of practice expansions that threaten patient safety. Both in Congress and at the state level, the AMA is pushing back on pharmacists’ efforts to inappropriately expand their scope of practice.

Building on AMA advocacy

The delegates’ latest actions build on existing AMA policy and ongoing advocacy efforts. In 2023, the House of Delegates adopted policy that “deems inappropriate inquiries from pharmacies to verify the medical rationale behind prescriptions, diagnoses and treatment plans to be an interference with the practice of medicine and unwarranted.”

Other supportive language on this issue is found in AMA policy on drug formularies and therapeutic interchange, generic drugs and therapeutic and pharmaceutical alternatives by pharmacists.

Meanwhile, the AMA has worked with state medical associations such as those in Illinois and Minnesota to ensure that physicians’ prescribing orders are not impeded. Those states have seen two of the more promising state laws recently enacted help protect patients who rely on opioid therapy. The Illinois law enacted in 2025 includes several important provisions, including:

• “Decisions regarding the treatment of patients experiencing chronic pain shall be made by the prescriber with dispensing by the pharmacist in accordance with the corresponding responsibility as described in 21 CFR 1306.04(a) and 77 Ill. Adm. Code 3100.380(a).”
• “Ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not in any way be predetermined by specific morphine milligram equivalent guidelines except as provided under federal law.”

And in 2024, Minnesota enacted a more comprehensive set of provisions that include:

• “No physician, advanced practice registered nurse, or physician assistant, acting in good faith and based on the needs of the patient, shall be subject to disenrollment or termination by the commissioner of health solely for prescribing a dosage that equates to an upward deviation from morphine milligram equivalent dosage recommendations or thresholds specified in state or federal opioid prescribing guidelines or policies, including but not limited to the Guideline for Prescribing Opioids for Chronic Pain issued by the Centers for Disease Control and Prevention and Minnesota opioid prescribing guidelines.”
• “A physician, advanced practice registered nurse, or physician assistant treating intractable pain by prescribing, dispensing, or administering a controlled substance in Schedules II to V of section 152.02 that includes but is not limited to opioid analgesics must not taper a patient’s medication dosage solely to meet a predetermined morphine milligram equivalent dosage recommendation or threshold if the patient is stable and compliant with the treatment plan, is experiencing no serious harm from the level of medication currently being prescribed or previously prescribed, and is in compliance with the patient-provider agreement as described in subdivision 5.”
• “A physician’s, advanced practice registered nurse’s, or physician assistant’s decision to taper a patient’s medication dosage must be based on factors other than a morphine milligram equivalent recommendation or threshold.”
• “No pharmacist, health plan company, or pharmacy benefit manager shall refuse to fill a prescription for an opiate issued by a licensed practitioner with the authority to prescribe opiates solely based on the prescription exceeding a predetermined morphine milligram equivalent dosage recommendation or threshold.” 

Filed under: General Problems | Leave a Comment »

If you click on the graphic, it will enlarge, might have to click it a second time to enlarge it a little more and/or magnify on your laptop screen with “CTRL” + “+” key… this was a graphic that someone else made and I just copied & paste into the post.

Filed under: General Problems | 2 Comments »

Trump Cabinet teams up to end animal abuse

Bondi says prosecutors will be placed in every state to handle animal cruelty cases

https://www.foxnews.com/media/trump-administration-launches-multi-agency-strike-force-crack-down-animal-abuse

https://www.foxnews.com/video/6386776126112

Senior officials in President Donald Trump’s administration say they are cracking down on animal cruelty, rolling out coordinated actions across the Justice Department, the Department of Agriculture (USDA) and the Department of Health and Human Services (HHS) to target dogfighting, puppy mills and animal testing.

“We are forming a strike force… and we’re going to have designated U.S. attorneys in every state to prosecute these [animal abuse] cases,” said Attorney General Pam Bondi on “My View with Lara Trump” on Saturday.

Bondi appeared with Agriculture Secretary Brooke Rollins and Health and Human Services Secretary Robert F. Kennedy Jr. to discuss their inter-agency animal welfare initiative.

Bondi said her department would work with the USDA to conduct special training for prosecutors and law enforcement agents on executing search warrants in animal abuse cases.

“We just last week convicted someone, for the first time ever, of using a firearm in a violent crime, and the violent crime was dogfighting,” Bondi said.

In another example that shows “no one is above the law,” Bondi told host Lara Trump that 190 dogs were seized from former NFL player LeShon Johnson. 

“That was the most seized from one single defendant. So we’re coming after you if you’re going after these babies,” she said, holding a small black puppy named Guru in her lap.

Rollins said the USDA is taking a tougher approach to shutting down abusive puppy mills, moving away from issuing warnings and toward stricter enforcement of the Animal Welfare Act.

“Compliance with the Animal Welfare Act, which is from the 1960s, was hovering around 65, 67% until the last few years. We’re now closer to 92%, but it’s that 8% that we’re really going to focus on.”

She described the poor conditions dogs can face in these mass-breeding operations. “No more puppy mills where you have puppies stacked on top of each other, where, if you don’t sell them, then you drown them in a barrel because it’s the cheapest way to do it.”

Kennedy said all the major sub-agency heads at HHS are “all deeply committed to ending animal experimentation.”

He said new studies on animal testing show “that the predictivity of animal models is very, very poor for human health outcomes. There are much more efficient ways of predicting human health outcomes. We are using, even in their nascent stages, computational modeling and AI,” which he said provides much better results.

The HHS chief said there are about 100,000 primates in research labs across the country.

“There are another 20,000 that are imported every year, and we’re very concerned about that. We’re trying to put an end to that completely,” he said, adding that his department was “re-educating researchers” to improve the predictability of human health outcomes. 

In September, the National Institutes of Health (NIH) changed its rules to ensure funding could be used to “retire their primates to sanctuaries after the experimentation is done.”

“Until now, there was no option like that, no alternative, except the researcher euthanized that animal after they were through. Now we’re developing sanctuaries across the country,” he said.

I made this post on Laura (Trump) My view on “saving dogs/animals – not one “like” or another post about chronic pain pts being harmed.”

“The moral test of a government is how it treats those who are at the dawn of life, the children; those who are in the twilight of life, the aged; and those who are in the shadow of life, the sick and the needy, and the handicapped.” – Hubert Humphrey, Pharmacist, VP

So the harm to dogs/animals is important to the “general public” but just like chronic pain pts die/suicide. Doesn’t that give you the “warm fuzzies” on how the general population concern about chronic pain pts being harmed? Interesting show concerning the protecting of animals, likewise this week I got a text from our Indiana Senator Jim Banks – with a one question survey about my position on abortion.. and about saving more lives. I am a retired Pharmacist and there is abt 100 + million chronic pain pts that the DEA is interfering with chronic pain pts getting their necessary and legally prescribed medications. The DEA is forcing – thru intimidation – for prescribers, drug wholesalers, pharmacies/pharmacist to reduce or stop their medically necessary medications. Forcing them to use the MME system (Morphine Milligram Equivalents) that has no real clinical studies supporting it conclusions and ignoring/ totally discounting DNA testing ( Pharmacogenomic testing) that does have real clinical studies that document that a pt’s liver metabolism affect the amount of medication(s) they need. Resulting in untold number of chronic pain pts to be forced to live/exist in a torturous level of pain, and be home, bed, chair confined because they can’t get their necessary medications prescribed or filled. These chronic pain pts are being forced to go to the street to try and get relief from their pain and end up dying from “illicit street opioids” or end up committing suicide. Why is our society not interested in saving these lives?

Filed under: General Problems | Leave a Comment »

Methadone can be a excellent med for pain management, but a decade ago either the state of Washington or Oregon had a mandate that all chronic pain pts that were on Medicaid, could only have Methadone prescribed for pain management, because Methadone was the least expensive opioid. They were having 2-4 pts for every 1,000 chronic pain pts  die from either a cardiac event or overdosed when first put on Methadone.

Generally, pts being prescribed Methadone should have a ECG before starting Methadone and repeated 6 months and 12 months after first prescribed Methadone and then a ECG annually while continuing to take Methadone. Also, the initial dosing of Methadone, the pt’s dose should be titrated up slowly. 

Apparently, when that state initiated a mandatory Methadone prescribing for chronic pain pts on Medicaid, no one tried to educate practitioners on the proper protocol for starting a pt on Methadone for pain management.

Countries using diamorphine (Herion) as analgesic

• United Kingdom

  • Diamorphine is licensed and can be prescribed for acute pain (post‑op, MI, trauma), chronic pain, and palliative care, although morphine is now preferred in many services.

• Historically widely used in palliative medicine, including continuous SC infusions via syringe drivers at end of life.

  Hong Kong

  • Diamorphine is a Schedule 1 “dangerous drug” but remains available by prescription for medical use; non‑prescribed possession and trafficking carry very severe penalties.

    Parts of Europe (niche/regulated roles)

    • Several European countries (e.g., Switzerland, Germany, the Netherlands, Denmark, Spain, UK) have authorized diamorphine as a medicinal product, but primarily for heroin‑assisted treatment (HAT) in treatment‑refractory opioid dependence, not routine pain

      ---

Stop Sidelining Methadone: Make Primary Care an Option Again

https://www.acsh.org/news/2025/12/15/stop-sidelining-methadone-make-primary-care-option-again-49866

American primary-care doctors can prescribe methadone for pain—but not for addiction. Meanwhile, their counterparts in Australia, Canada, and the UK have used methadone to treat addiction for over 50 years. A new randomized controlled trial shows they were right the whole time.

In a Cato Institute policy analysis, Sofia Hamilton and I highlighted that people with opioid use disorder (OUD) in Australia, Canada, and the UK have been able to access methadone treatment through their primary care clinicians for over 50 years. Patients in the US could access treatment from their primary care clinicians before 1972, when the implementation of the Controlled Substance Act (CSA) resulted in the current system, which treats patients with OUD as if they were outcasts and requires them to line up at Drug Enforcement Administration-regulated opioid treatment programs (OTPs) to receive methadone under supervision and oversight.

When COVID-19 hit in March 2020, and daily trips to federally licensed methadone clinics became more difficult for people with OUD, the Substance Abuse and Mental Health Services Administration (SAMHSA) relaxed the rules. It allowed OTPs to provide “stable” patients with up to a 28-day take-home supply and enabled buprenorphine visits to occur via telehealth, rather than requiring in-person appointments. The program was a success. Follow-up studies found the policy improved patient compliance and did not cause buprenorphine or methadone diversion into the black market.

The reforms were compelling enough that SAMHSA eventually made them permanent. Follow-up studies by the Centers for Disease Control and Prevention (CDC) and National Institute on Drug Abuse (NIDA) researchers, published in JAMA Psychiatry in July 2022, showed that methadone-related overdose deaths did not rise after the policy change. The National Institutes of Health (NIH) reached a similar conclusion that month, noting that the proportion of overdose deaths involving methadone actually decreased from early 2019 to August 2021.

It often surprises people that the DEA permits any clinician with a standard narcotics license to prescribe methadone for pain, yet bans them from prescribing it for addiction treatment. According to the National Institute on Drug Abuse, “Methadone diversion is primarily associated with methadone prescribed for the treatment of pain and not for the treatment of opioid use disorders. In one survey, giving methadone away was identified as the most common form of methadone diversion, which aligns with other findings that 80 percent of people who report diverting methadone did so to help others who misused substances.” (emphasis added)

Our policy analysis cited federal pilot programs that have already shown that when primary care clinicians are permitted to prescribe methadone for opioid use disorder, the results in the US are as strong as those long observed in Australia, Canada, and the UK. One such program, overseen by researchers at Yale University, randomly assigned 47 patients to six primary care clinicians and followed them for six months. It concluded:

Our results support the feasibility and efficacy of transferring stable opioid-dependent patients receiving methadone maintenance to primary care physicians’ offices for continuing treatment and suggest guidelines for identifying patients and clinical monitoring.

Today, a new study funded by NIDA was published in the Annals of Internal Medicine, providing even more substantial evidence that allowing primary care clinicians to treat OUD patients with methadone is safe and effective. Yale researchers conducted a randomized controlled trial involving 1,459 adults (905 in the intervention group and 509 in the control group), who received methadone treatment from primary care clinicians supported by telemonitoring across 13 cities in Ukraine. The control group received “standard specialty clinic care.”

The primary outcome they assessed was an overall quality-of-care score at 24 months, based on whether patients received 17 recommended services across primary and specialty care. They also analyzed each category separately—“domain scores,” which show how patients performed within specific areas of care—and several indicators related to methadone treatment.

Patients treated in primary care did better across the board. After two years, they scored about nine points higher on the overall quality-of-care measure than those treated in traditional methadone clinics. The advantage appeared in both primary and specialty care services. When it came to staying on methadone, new patients in primary care were slightly more likely to stay in treatment at 24 months—67 percent versus about 65 percent in specialty programs. Their conclusion:

Integrating methadone treatment into primary care settings improves adherence to guideline-concordant health care without compromising methadone retention and treatment quality.

The research keeps pointing in one direction: patients benefit when methadone is available in primary care.

One week from today, the Cato Institute will host a screening of the award-winning documentary “Shuffle.” Filmmaker Ben Flaherty demonstrates how federal rules—especially those embedded in the Affordable Care Act and Medicaid—have unintentionally allowed predatory rehab operators to profit from the suffering of people with substance use disorder, who deserve care, not exploitation. Instead of reducing harm, these mandates might be supporting—and even expanding—the very problems they were intended to resolve.

In our policy analysis, Hamilton and I argued that letting primary care clinicians prescribe methadone would expand access to effective treatment, reduce overdose deaths, and help more people with OUD reclaim their lives. After seeing in the film how predatory rehab clinics exploit vulnerable patients and siphon off health-care dollars, there’s another clear advantage: expanding office-based methadone would shrink the pool of people these operators can target.

(You can register for the film screening here. The screening will be in-person only, but the panel discussion that follows it will be livestreamed.)

Filed under: General Problems | Leave a Comment »